EDAP Announces Ablatherm Fusion World Premiere during American Urology Association Annual Meeting in Boston, MA, May 12-16, 2...
May 11 2017 - 7:30AM
EDAP Announces Ablatherm Fusion World
Premiere during American Urology Association Annual Meeting in
Boston, MA, May 12-16, 2017
EDAP to Showcase Ablatherm Fusion and Sonolith
i-move at AUA Booth #130
LYON, France, May 11, 2017 -- EDAP TMS SA (Nasdaq:EDAP), the
global leader in therapeutic ultrasound, announced today that it
will demonstrate capabilities of its range of products including
Ablatherm® Robotic HIFU and Sonolith i-move lithotripter on booth
#130 at the American Urology Association ("AUA") Annual Meeting, to
be held May 12-16, 2017 in Boston, MA. Live demonstrations will be
conducted by experts from world-class US and
International academic centers throughout the meeting. Key opinion
leaders and experts will be participating in sessions where HIFU
technology will be discussed and clinical results of HIFU for
ablation of the prostate presented.
During AUA, EDAP will also present the
world premiere of the Ablatherm® Fusion, the next
generation of the Ablatherm Robotic HIFU device integrating EDAP's
proprietary elastic fusion algorithm. This new device will allow
urologists to import pre-treatment diagnostic information such as
MRI images and 3D biopsy maps and merge them with the live
ultrasound image during the procedure. This new, innovative device
creates a distinct advantage positioning Ablatherm Robotic HIFU as
the ideal device for prostate tissue ablation by increasing and
improving its capacity to provide optimal patient treatment and to
preserve patient quality of life.
Marc Oczachowski, EDAP's Chief Executive Officer, commented: "We
are thrilled to introduce this innovative product that enables
novel therapeutic strategies for the ablation of prostate tissues.
Additionally, this expansion to our range of HIFU offerings creates
a new option for hospitals and urologists, allowing EDAP to serve a
broader range of customers at a variety of price points."
About EDAP TMS SA
EDAP TMS SA markets today Ablatherm® for high-intensity focused
ultrasound (HIFU) for prostate tissue ablation in the U.S. and
for treatment of localized prostate cancer in the rest of
the world. HIFU treatment is shown to be a minimally invasive and
effective option for prostatic tissue ablation with a low
occurrence of side effects. Ablatherm-HIFU is generally recommended
for patients with localized prostate cancer (stages T1-T2) who are
not candidates for surgery or who prefer an alternative option, or
for patients who failed radiotherapy treatment. Ablatherm-HIFU is
approved for commercial distribution in Europe and some other
countries including Mexico and Canada, and has received
510(k) clearance by the U.S. FDA. Ablatherm Fusion is not yet
available in the U.S. The Company also markets an innovative
robot-assisted HIFU device, the Focal One®, dedicated to focal
therapy of prostate cancer. Focal One® is CE marked but is not FDA
cleared. The Company also develops its HIFU technology for the
potential treatment of certain other types of tumors. EDAP TMS SA
also produces and distributes medical equipment (the Sonolith®
lithotripters' range) for the treatment of urinary tract stones
using extra-corporeal shockwave lithotripsy (ESWL) in most
countries including Canada and the U.S. For more information on the
Company, please visit http://www.edap-tms.com,
and http://www.hifu-planet.com.
Forward
Looking Statements
In addition to historical information, this press release may
contain forward-looking statements. Such statements are based on
management's current expectations and are subject to a number of
risks and uncertainties, including matters not yet known to us or
not currently considered material by us, and there can be no
assurance that anticipated events will occur or that the objectives
set out will actually be achieved. Important factors that could
cause actual results to differ materially from the results
anticipated in the forward-looking statements include, among
others, the clinical status and market acceptance of our HIFU
devices and the continued market potential for our lithotripsy
device. Factors that may cause such a difference also
may include, but are not limited to, those described in
the Company's filings with the Securities and Exchange Commission
and in particular, in the sections "Cautionary Statement on
Forward-Looking Information" and "Risk Factors" in the Company's
Annual Report on Form 20-F.
Investor Contact
CG CAPITALRich
Cockrell877.889.1972investorrelations@cg.capital
Company Contact
Blandine ConfortInvestor Relations / Legal Affairs EDAP TMS
SA+33 4 72 15 31 50bconfort@edap-tms.com
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Mar 2024 to Apr 2024
EDAP TMS (NASDAQ:EDAP)
Historical Stock Chart
From Apr 2023 to Apr 2024